Biogened Statistics

Total Valuation

Biogened has a market cap or net worth of PLN 76.15 million. The enterprise value is 97.57 million.

Market Cap	76.15M
Enterprise Value	97.57M

Important Dates

The next estimated earnings date is Friday, February 14, 2025.

Earnings Date	Feb 14, 2025
Ex-Dividend Date	Sep 12, 2024

Share Statistics

Biogened has 2.46 million shares outstanding.

Current Share Class	n/a
Shares Outstanding	2.46M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	n/a
Owned by Institutions (%)	1.17%
Float	144,714

Valuation Ratios

The trailing PE ratio is 15.63.

PE Ratio	15.63
Forward PE	n/a
PS Ratio	0.71
PB Ratio	1.94
P/TBV Ratio	1.96
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 7.83, with an EV/FCF ratio of -69.09.

EV / Earnings	20.03
EV / Sales	0.91
EV / EBITDA	7.83
EV / EBIT	11.56
EV / FCF	-69.09

Financial Position

The company has a current ratio of 2.25, with a Debt / Equity ratio of 0.70.

Current Ratio	2.25
Quick Ratio	1.19
Debt / Equity	0.70
Debt / EBITDA	2.21
Debt / FCF	-19.54
Interest Coverage	3.74

Financial Efficiency

Return on equity (ROE) is 12.99% and return on invested capital (ROIC) is 8.40%.

Return on Equity (ROE)	12.99%
Return on Assets (ROA)	6.41%
Return on Invested Capital (ROIC)	8.40%
Return on Capital Employed (ROCE)	13.29%
Revenue Per Employee	498,682
Profits Per Employee	22,656
Employee Count	209
Asset Turnover	1.30
Inventory Turnover	1.50

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +60.00% in the last 52 weeks. The beta is 0.80, so Biogened's price volatility has been lower than the market average.

Beta (5Y)	0.80
52-Week Price Change	+60.00%
50-Day Moving Average	23.16
200-Day Moving Average	23.61
Relative Strength Index (RSI)	71.84
Average Volume (20 Days)	87

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Biogened had revenue of PLN 107.22 million and earned 4.87 million in profits. Earnings per share was 1.98.

Revenue	107.22M
Gross Profit	75.54M
Operating Income	8.44M
Pretax Income	6.55M
Net Income	4.87M
EBITDA	12.46M
EBIT	8.44M
Earnings Per Share (EPS)	1.98

Full Income Statement

Balance Sheet

The company has 6.16 million in cash and 27.59 million in debt, giving a net cash position of -21.43 million or -8.72 per share.

Cash & Cash Equivalents	6.16M
Total Debt	27.59M
Net Cash	-21.43M
Net Cash Per Share	-8.72
Equity (Book Value)	39.32M
Book Value Per Share	16.01
Working Capital	29.22M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 4.68 million and capital expenditures -6.10 million, giving a free cash flow of -1.41 million.

Operating Cash Flow	4.68M
Capital Expenditures	-6.10M
Free Cash Flow	-1.41M
FCF Per Share	-0.57

Full Cash Flow Statement

Margins

Gross margin is 70.46%, with operating and profit margins of 7.88% and 4.54%.

Gross Margin	70.46%
Operating Margin	7.88%
Pretax Margin	6.11%
Profit Margin	4.54%
EBITDA Margin	11.62%
EBIT Margin	7.88%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 0.50, which amounts to a dividend yield of 1.61%.

Dividend Per Share	0.50
Dividend Yield	1.61%
Dividend Growth (YoY)	25.00%
Years of Dividend Growth	3
Payout Ratio	20.17%
Buyback Yield	n/a
Shareholder Yield	1.61%
Earnings Yield	6.40%
FCF Yield	-1.85%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Biogened has an Altman Z-Score of 2.71. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.71
Piotroski F-Score	n/a